1.58Open1.58Pre Close0 Volume31 Open Interest22.50Strike Price0.00Turnover50.58%IV3.84%PremiumDec 20, 2024Expiry Date0.69Intrinsic Value100Multiplier23DDays to Expiry0.89Extrinsic Value100Contract SizeAmericanOptions Type0.6261Delta0.1275Gamma14.68Leverage Ratio-0.0258Theta0.0083Rho9.19Eff Leverage0.0223Vega
MeridianLink Stock Discussion
Reported strong third-quarter results and continues to benefit from the accelerated digital transformation of financial services. The Company continues to add new quality customers and expand its relationships with existing customers in a wide range of markets, including lenders, financial service providers and information providers. Continue to expand further into adjacent markets and expand its product offering with increasing services and enhanced data validation, including the ability to provide repeated background checks to reduce risk and add new features to its advanced QuickApp tool to enable its customers to better serve their customers
$Elicio Therapeutics (ELTX.US)$ $Candel Therapeutics (CADL.US)$ $Context Therapeutics (CNTX.US)$ $Dole plc (DOLE.US)$ $Duolingo (DUOL.US)$ $MeridianLink (MLNK.US)$ $PowerSchool (PWSC.US)$ $Snap One (SNPO.US)$ $Icosavax (ICVX.US)$ $Preston Hollow Community Capital (PHCC.US)$ $Rallybio (RLYB.US)$ $Riskified (RSKD.US)$
No comment yet